Eurofins Scientific

Healthy H1 FY20 results; momentum expected to continue

13/08/20 -"Despite trimmed EPS estimates, our target price has increased slightly, as we have reduced our debt spread estimate in the DCF valuation, considering Eurofins' improved leverage profile / significant ..."

PDF page sample
Pages
46
Language
English
Published on
13/08/20
Download
You may also be interested by these reports :
24/04/24
Eurofins Scientific reported a Q1 2024 trading update slightly below the street’s expectations. While organic sales growth in the core business ...
23/04/24
Randstad was impacted by tough market conditions in all its geographies. Organic revenue per working day decreased by -7.8%. North America and ...
19/04/24
Rentokil Initial reported a weak Q1 FY24 trading update, with sales slightly below the street’s and our expectations. Notably, demand in the North ...
12/04/24
At its CMD, Bureau Veritas unveiled a new set of financial targets. Under its new strategy, the group is targeting high single-digit revenue growth ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO